Recent Publications
- Pretransplant promise for PD-1 in Hodgkin lymphoma March 5, 2026No abstract
- Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups January 13, 2026CONCLUSION: The cumulative burden of high-risk cytogenetic abnormalities predicts inferior survival in NDMM, underscoring the need for refined risk stratification and tailored therapeutic strategies.
- Clinical parameters of patients with Duffy null phenotype: a single centre, retrospective review February 20, 2025We characterise the clinical parameters of patients referred for isolated neutropenia who were found to express the Duffy null phenotype and subsequent diagnosis of Duffy null associated neutrophil count (DANC). This is a single-centre, retrospective review of adult patients (18 years and over) who were referred to a tertiary hospital for further investigation of isolated […]
- Treating asymptomatic follicular lymphoma: What is the score? December 19, 2024Health-related quality of life measures are underemphasised in clinical trials and particularly valuable in follicular lymphoma as some interventions can result in substantial toxicity with uncertain impact on overall survival. The report by Marzolini and colleagues provides a nuanced discussion on the merits of rituximab monotherapy versus observation in asymptomatic follicular lymphoma patients. Commentary on: […]
- Long-term efficacy and safety of chemotherapy-free first-line iodine-131-rituximab radioimmunotherapy of follicular lymphoma August 9, 2021No abstract